Joaquim Bellmunt

Medical Oncoloy, IMIM, Spain

Dr. Bellmunt is Assistant Professor of Medicine at the UPF in Barcelona and Chief of the Solid Tumor Oncology Section at the Medical Oncology Service of Hospital del Mar, Barcelona. He is President and Co-founder of the Spanish Oncology Genitourinary Group (SOGUG). He is also a Consultant for the EORTC - GU Group and Chairman of the group’s Advanced Bladder Committee.

He received his medical and doctorate degrees from the Universidad Autonoma of Barcelona and then obtained his European Certificate of Medical Oncology in London before completing his Medical Oncology Residency at the Vall d’Hebron University Hospital in Barcelona. He worked as an assistant at the Laboratory of Immunology, Hospital Infantil de la Ciudad Sanitaria Valle Hebrón and visited at the Clinical Immunology Service, the Division of Medical Oncology, and the Department of Immunopathology at the Memorial Sloan-Kettering Cancer Center, New York. After completion of his residency, Dr. Bellmunt joined the Medical Oncology Service staff at the of Valle d’Hebron where he was responsible for the Uro-oncological Unit.

His research interests lie in clinical genitourinary (GU) oncology including new drugs, translational and early clinical research in the area of growth factor receptors and downstream molecules as targets for cancer therapy. He has been involved in the clinical development of several new agents and combinations including the M-CAVI combination in unfit patients, PCG triplet, carboplatin, gemcitabine, GW2016, 2C4, vinflunine, sorafenib, sunitinib and other agents. He also has served as an advisory board member on new agents like sorafenib, sunitinib, pazopanib, revlimid, bortezomib and other targeted therapies.

Dr. Bellmunt is an active member of the European Society of Medical Oncology and the American Society of Clinical Oncology. He was a member of the ASCO Program GU-Committee from 2003 to 2005. He is member of the EORTC GU Group and is the Coordinator of the Intergroup study in advanced transitional Cancer (EORTC 30987) and is also co-coordinator of the EORTC 30986 study in unfit patients.

Dr. Bellmunt serves as ad hoc reviewer for the Journal of Clinical Oncology, Annals of Oncology, European Urology, European Journal of Cancer, British Journal of Urology Int. and the Journal of Urology among others. Dr. Bellmunt has published over 70 peer-reviewed articles and over 100 abstracts and book chapters.

Any competing interests declared are displayed with individual evaluations.

Faculty Member: Oncology > Genitourinary Cancers (since 05 November 2007)

All recent recommendations

• 6.0
  Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.
  Recommended by Joaquim Bellmunt